Comparability of blinded remote and site-based assessments of response to adjunctive esketamine or placebo nasal spray in patients with treatment resistant depression-Reference-Cited by-同舟云学术

Comparability of blinded remote and site-based assessments of response to adjunctive esketamine or placebo nasal spray in patients with treatment resistant depression

Published:2019-04 Issue: Volume:111 Page:68-73
ISSN:0022-3956
Container-title:Journal of Psychiatric Research
language:en
Short-container-title:Journal of Psychiatric Research

Author:

Targum S.D.^ORCID,Daly E.,Fedgchin M.,Cooper K.,Singh J.B.

Funder

Janssen Research & Development

Acadia Pharmaceuticals

Alkermes Inc.

Functional Neuromodulation Inc.

Intracellular Therapeutics

Karuna, Methylation Sciences Inc.

Navitor Pharmaceuticals

Neurim Pharmaceuticals

Pfizer Inc.

Prana Biotechnology Ltd.

Resilience Therapeutics

Sunovion

Publisher

Elsevier BV

Subject

Biological Psychiatry,Psychiatry and Mental health

Reference19 articles.

1. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV);American Psychiatric Association,2000

2. Measurement of dissociative states with the clinician-administered dissociative states scale (CADSS);Bremner;J. Trauma Stress,1998

3. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled Study;Canuso;Am. J. Psychiatr. Adv.,2018

4. Validation of the Massachusetts general hospital antidepressant treatment history Questionnaire (ATRQ);Chandler;CNS Neurosci. Ther.,2010

5. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial;Daly;JAMA Psychiatr.,2017

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Use of video-recordings of site-based interviews for quality assurance in a study of subjects with schizophrenia and persistent negative symptoms;Schizophrenia Research;2024-10

2. A qualitative investigation of the Montgomery–Åsberg depression rating scale: discrepancies in rater perceptions and data trends in remote assessments of rapid-acting antidepressants in treatment resistant depression;Frontiers in Psychiatry;2024-05-01

3. Potentiation of antidepressant effects: NPY1R agonist and ketamine synergy enhances TrkB signaling and neurogenesis in the ventral hippocampus;Expert Opinion on Therapeutic Targets;2024-04-02

4. Exploring Esketamine's Therapeutic Outcomes as an FDA-Designated Breakthrough for Treatment-Resistant Depression and Major Depressive Disorder With Suicidal Intent: A Narrative Review;Cureus;2024-02-10

5. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial;Nature Medicine;2023-09-14